Dual-payload Her2 ADC (MediLink Therapeutics)

N/A

Report date: 2025/08/22 17:00:34

Base Information

Drug NameDual-payload Her2 ADC (MediLink Therapeutics)
Drug Alias NameDual-payload ADC (MediLink Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitorsTubulin inhibitorsAnti-HER2
TargetsTubulinDNA topoisomerase IReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMediLink Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMediLink Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A